本帖最后由 老马 于 2013-3-13 13:43 编辑
5 x3 l. m3 j9 K; o- j) b w x/ ?3 @+ e7 t; u- c+ y8 ~
健择（吉西他滨）+顺铂+阿瓦斯汀
1 T) a6 z# B, q$ [2 u0 Z# `0 w Gemzar +Cisplatin + Avastin; @8 F8 A8 \- [: m6 p o% O3 S" b
http://annonc.oxfordjournals.org/content/21/9/1804.full' Z6 [& z$ G8 o" n6 D
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) b: c8 A7 D7 Y) t/ J
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
A! }3 k `5 j! ~( iResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 1 l/ a- I+ H' X3 u: b
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 855)
: k/ K& C0 b. R9 W0 o# Z# P0 V华为网盘附件：
: a) u0 L* z4 a【华为网盘】ava.JPG: R6 B' V0 h9 v/ U. p( |0 ^ E
|
显身卡
